Glycan Therapeutics is a therapeutics company. The company has a unique patented technology for synthesizing heparin and heparan sulfate oligosaccharides for medical uses.
Glycan Therapeutics is developing new drug therapies that are based on a novel synthetic carbohydrate technology platform. The platform technology is used to synthesize an anticoagulant drug, like synthetic heparin, and also design heparin-like oligosaccharides for the purpose of research and development for medical applications.
The company engages in the development of enzymatically synthesized sulfated oligosaccharides for varieties of indications. While aiming to develop a cost-effective method to prepare synthetic heparin, the company is also preparing a wide range of homogeneous heparin oligosaccharide products for researchers to investigate the role of these products in vascular biology, developmental biology and infectious diseases. Glycan Therapeutics has been supported by SBIR contracts from the National Cancer Institute.